Hims & Hers faces backlash over ‘misleading' Super Bowl ad—but it didn't stop stock from jumping over 11%
Portfolio Pulse from
Hims & Hers Health is under scrutiny after its Super Bowl ad was labeled 'misleading' by a major drug industry lobbying group. Despite this, the company's stock rose over 11%.
February 09, 2025 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Hims & Hers Health's stock rose over 11% despite backlash from a drug industry group over its Super Bowl ad, which was called 'misleading'.
The stock price increase suggests that investors are not significantly concerned about the backlash or potential marketing rule violations. The 11% rise indicates positive market sentiment or other factors outweighing the negative press.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100